| Identification | Back Directory | [Name]
Benzeneacetamide, 4-nitro-N-(4-nitrophenyl)-α-[phenyl[4-(trifluoromethyl)benzoyl]amino]- | [CAS]
2581824-39-5 | [Synonyms]
MMP-9-IN-4
Benzeneacetamide, 4-nitro-N-(4-nitrophenyl)-α-[phenyl[4-(trifluoromethyl)benzoyl]amino]- | [Molecular Formula]
C28H19F3N4O6 | [MOL File]
2581824-39-5.mol | [Molecular Weight]
564.48 |
| Hazard Information | Back Directory | [Uses]
MMP-9-IN-4 is a MMP-9 inhibitor (IC50: 7.46 nM) that has H-π interactions with MMP-9. MMP-9-IN-4 also inhibits AKT activity (IC50: 8.82 nM). MMP-9-IN-4 shows cell cytotoxicity and induces cell apoptosis. MMP-9-IN-4 can be used in the research of cancers[1]. | [IC 50]
MMP-9: 7.46 nM (IC50); MMP-1: 41 nM (IC50); MMP-2: 139 nM (IC50); MMP-13: 113 nM (IC50); AKT: 8.82 nM (IC50) | [References]
[1] Mohammed Salah Ayoup, et al. Battle tactics against MMP-9; discovery of novel non-hydroxamate MMP-9 inhibitors endowed with PI3K/AKT signaling attenuation and caspase 3/7 activation via Ugi bis-amide synthesis. Eur J Med Chem. 2020 Jan 15;186:111875. DOI:10.1016/j.ejmech.2019.111875 |
|
|